Dual Inhibition of Pirarubicin-Induced AKT and ERK Activations by Phenformin Sensitively Suppresses Bladder Cancer Growth
Open Access
- 8 October 2019
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 10, 1159
Abstract
Activations of Akt or ERK pathway induced by clinical drugs promote therapeutic failure due to decrease of drug response, and no available strategies have been developed to solve these problems. In this study, we found that pirarubicin (THP), one important chemotherapeutic drug for treating bladder cancer intravesically, dramatically elevated phosphorylations of both Akt and Erk1/2 in addition to inducing DNA damage. MK2206 or AZD6244, representative Akt and Erk1/2 inhibitors, respectively, profoundly sensitized bladder cancer cells to THP treatment. Interestingly, we found that inhibition of a single arm of either Akt or Erk1/2 pathway would induce the increase of another arm, indicating the existence of the crosstalk between these two pathways. Thus, simultaneous suppression of both signals may be needed for increasing the sensitivity of THP. On the other hand, we revealed that phenformin efficiently inhibited both Akt and Erk1/2 phosphorylation in a dose-dependent manner. Furthermore, we demonstrated that phenformin, mimicking dual inhibitors, plays dramatically synergistic action with THP both in vitro and in vivo. Our findings suggest that combination therapy of THP with dual inhibitors may constitute a successful strategy for improving chemotherapy response.Keywords
Funding Information
- National Natural Science Foundation of China (81703008, 81874212)
- Natural Science Foundation of Hunan Province (2018JJ3831, 2016JJ2187)
- Xiangya Hospital, Central South University (2016Q02)
- Hunan Normal University (840140-008)
This publication has 54 references indexed in Scilit:
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensationTrends in Biochemical Sciences, 2011
- ERK and Akt signaling pathways function through parallel mechanisms to promote mTORC1 signalingAmerican Journal of Physiology-Cell Physiology, 2011
- Molecular pathways of urothelial development and bladder tumorigenesisUrologic Oncology: Seminars and Original Investigations, 2010
- MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted DrugsIn vitroandIn vivoMolecular Cancer Therapeutics, 2010
- Recurrence and Progression of Disease in Non–Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment StrategyEuropean Urology, 2009
- Molecular Pathogenesis and Diagnostics of Bladder CancerAnnual Review of Pathology: Mechanisms of Disease, 2009
- Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistanceBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2007
- RE: A SINGLE IMMEDIATE POSTOPERATIVE INSTILLATION OF CHEMOTHERAPY DECREASES THE RISK OF RECURRENCE IN PATIENTS WITH STAGE Ta T1 BLADDER CANCER: A META-ANALYSIS OF PUBLISHED RESULTS OF RANDOMIZED CLINICAL TRIALSJournal of Urology, 2005
- In vitro chemosensitivity test for human genito-urinary tumors using collagen gel matrixInternational Journal of Urology, 2005